AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31154309 — intervention group
Group type: COMPARATOR
Intervention: No intervention control condition.
Number of subjects: 0
Study 31154309 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week intervention.
Number of subjects: 0
Study 28882655 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief in-hospital psychological intervention (two 1 h 15 min sessions and a 20-minute follow-up session)
Number of subjects: 121
Study 28882655 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical care without psychological intervention)
Number of subjects: 121
Study 25273982 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (scheduled clamping and unclamping of the trans-urethral catheter every three hours)
Number of subjects: 111
Study 25273982 — intervention group
Group type: COMPARATOR
Intervention: Control (no bladder training)
Number of subjects: 111
Study 25084625 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (The Academy for Future Science Faculty) including annual in-person meetings and ongoing virtual coaching.
Number of subjects: 0
Study 25084625 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 22179079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.25 mg)
Number of subjects: 35
Study 22179079 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 μg)
Number of subjects: 35
Study 22179079 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study 20960541 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PCI (≤6 hours) with double bolus of eptifibatide
Number of subjects: 54
Study 20960541 — intervention group
Group type: COMPARATOR
Intervention: Early PCI (7‐72 hours) with upstream eptifibatide
Number of subjects: 54
Study 17693888 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1452 alone
Number of subjects: 160
Study 17693888 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1452 plus MN rgp120
Number of subjects: 160
Study 17693888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 15709843 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-administered cognitive-behavioral intervention
Number of subjects: 0
Study 15709843 — intervention group
Group type: COMPARATOR
Intervention: Monitoring-control condition
Number of subjects: 0
Study 15177064 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200mg
Number of subjects: 15
Study 15177064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10784384 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant supplement (beta-carotene, lycopene, lutein, canthaxanthin, alpha-tocopherol) without dietary fiber
Number of subjects: 6
Study 10784384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement with pectin
Number of subjects: 6
Study 10784384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement with guar
Number of subjects: 6
Study 10784384 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement with cellulose
Number of subjects: 6
Study 7597693 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic electrical stimulation (TES) applied to the affected muscles in the right upper and lower extremities for more than 3 months.
Number of subjects: 1
Study 7597693 — intervention group
Group type: COMPARATOR
Intervention: Non-treated side (left side) without TES intervention.
Number of subjects: 1
Study 2192771 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-ACE
Number of subjects: 0
Study 2192771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6989687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 100 mg slow-release tablets (morning or evening dose)
Number of subjects: 148
Study 6989687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg enteric-coated tablets b.i.d.
Number of subjects: 148
Study 6989687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 30908338 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lens with 0.019 mg ketotifen
Number of subjects: 244
Study 30908338 — intervention group
Group type: COMPARATOR
Intervention: Control lens with no added drug
Number of subjects: 244
Study 28294499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide/glargine
Number of subjects: 300
Study 28294499 — intervention group
Group type: COMPARATOR
Intervention: Placebo/glargine
Number of subjects: 300
Study 28294499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 300
Study 25757954 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with visual biofeedback
Number of subjects: 50
Study 25757954 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training without visual biofeedback
Number of subjects: 50
Study 23570863 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg QD for 15 days with OC
Number of subjects: 20
Study 23570863 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg QD for 15 days with OC
Number of subjects: 20
Study 23570863 — intervention group
Group type: COMPARATOR
Intervention: OC alone (30 μg ethinylestradiol and 150 μg levonorgestrel)
Number of subjects: 20
Study 20972537 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based PISQ-12
Number of subjects: 52
Study 20972537 — intervention group
Group type: COMPARATOR
Intervention: Paper-based PISQ-12
Number of subjects: 52
Study 19906341 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/d; flexible doses: 100-400 mg/d)
Number of subjects: 2913
Study 19906341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2913
Study 17881750 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat doses of antenatal corticosteroids (11.4 mg of betamethasone, intramuscular injection, repeated weekly if at risk for preterm delivery)
Number of subjects: 1085
Study 17881750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 1085
Study 17881750 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat doses of antenatal corticosteroids
Number of subjects: 1085
Study 17881750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1085
Study 16541760 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent disinfection by antiseptics
Number of subjects: 97
Study 16541760 — intervention group
Group type: COMPARATOR
Intervention: Surgical dressing without frequent disinfection
Number of subjects: 97
Study 12548591 — intervention group
Group type: EXPERIMENTAL
Intervention: AMGN-0007 (subcutaneously)
Number of subjects: 54
Study 12548591 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (90 mg intravenously)
Number of subjects: 54
Study 11780252 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol tablet, 3 times a day for 2 weeks, followed by 6 weeks of continued use for group B.
Number of subjects: 150
Study 11780252 — intervention group
Group type: COMPARATOR
Intervention: Placebo given to contrast group.
Number of subjects: 150
Study 11780252 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol tablet, after stopping use for 3 weeks.
Number of subjects: 150
Study 8780281 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 122
Study 8780281 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA) with IV propofol sedation
Number of subjects: 122
Study 1293241 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 therapy (100 micrograms t.d.s. for 5 days)
Number of subjects: 12
Study 6539322 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of 25% albumin solution
Number of subjects: 26
Study 6539322 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of 25% albumin solution
Number of subjects: 26
Study 6539322 — intervention group
Group type: COMPARATOR
Intervention: 100 ml of 0.9% saline
Number of subjects: 26
Study 6539322 — intervention group
Group type: COMPARATOR
Intervention: 200 ml of 0.9% saline
Number of subjects: 26
Study 31014399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFNα
Number of subjects: 35
Study 31014399 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 35
Study 31014399 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccine
Number of subjects: 35
Study 31014399 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune biomarker analysis
Number of subjects: 35
Study 27986795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuned waveform (3.5 ms time constant based)
Number of subjects: 91
Study 27986795 — intervention group
Group type: COMPARATOR
Intervention: Fixed tilt (50/50%)
Number of subjects: 91
Study 25496405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab infusion at a weekly dose of 375 mg/m2 for 4 weeks plus oral daily prednisolone
Number of subjects: 7
Study 25496405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab infusion
Number of subjects: 7
Study 23468513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping drug-eluting stents (R-ZES or R-ZES/other DES)
Number of subjects: 5130
Study 21114550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt (Co) 59mg intramuscular injection diluted in 5ml 0.9% saline solution twice a day
Number of subjects: 10
Study 21114550 — intervention group
Group type: COMPARATOR
Intervention: Control (5ml 0.9% saline solution intramuscular injection twice a day)
Number of subjects: 10
Study 18095751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive patch containing citrus oil and magnesium salts
Number of subjects: 48
Study 18095751 — intervention group
Group type: COMPARATOR
Intervention: Oral solution containing benzocaine and compound benzoin tincture
Number of subjects: 48
Study 17602057 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Pancreatectomy (TP)
Number of subjects: 0
Study 17602057 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Lymph Node Dissection (ELND)
Number of subjects: 0
Study 17602057 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Arterial Resection
Number of subjects: 0
Study 17602057 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal and/or Mesenteric Venous Resection
Number of subjects: 0
Study 15014007 — intervention group
Group type: EXPERIMENTAL
Intervention: ACA125 vaccine
Number of subjects: 119
Study 11500526 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin 0.3 mg/kilogram subcutaneously for 6 days
Number of subjects: 6
Study 11500526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9406129 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 30
Study 9406129 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8307916 — intervention group
Group type: EXPERIMENTAL
Intervention: endoscopic sclerotherapy along with ranitidine 300 mg daily
Number of subjects: 31
Study 8307916 — intervention group
Group type: COMPARATOR
Intervention: endoscopic sclerotherapy alone
Number of subjects: 31
Study 3500688 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (200 mg, orally)
Number of subjects: 20
Study 3500688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30062794 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium 7 g t.d.s.
Number of subjects: 29
Study 30062794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 27656054 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical clearing technique (ACT)
Number of subjects: 20
Study 27656054 — intervention group
Group type: COMPARATOR
Intervention: Conventional apical preparation (CAP)
Number of subjects: 20
Study 27656054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACT and CAP
Number of subjects: 20
Study 26022102 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of movement patterns augmented by motion-sensor movement biofeedback plus guidelines-based medical or physiotherapy care
Number of subjects: 112
Study 26022102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wearing the motion-sensors without biofeedback) plus guidelines-based medical or physiotherapy care
Number of subjects: 112
Study 22747899 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO-driven therapy
Number of subjects: 90
Study 22747899 — intervention group
Group type: COMPARATOR
Intervention: Standard management group (control)
Number of subjects: 90
Study 20185272 — intervention group
Group type: EXPERIMENTAL
Intervention: HARP program
Number of subjects: 80
Study 20185272 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 18237706 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture anchor fixation
Number of subjects: 14
Study 18237706 — intervention group
Group type: COMPARATOR
Intervention: Suture fixation to an intact labrum
Number of subjects: 14
Study 16357109 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmtop-assisted self-interviewing (PASI)
Number of subjects: 1283
Study 16357109 — intervention group
Group type: COMPARATOR
Intervention: Audio-computer-assisted self-interviewing (ACASI)
Number of subjects: 1283
Study 16357109 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 1283
Study 14582037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 3577
Study 14582037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3577
Study 10972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movement at slow speed
Number of subjects: 74
Study 10972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movement at fast speed
Number of subjects: 74
Study 10972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance at slow speed
Number of subjects: 74
Study 10972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance at fast speed
Number of subjects: 74
Study 10972410 — intervention group
Group type: COMPARATOR
Intervention: No-practice control task
Number of subjects: 74
Study 10972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movement (both slow and fast)
Number of subjects: 74
Study 10972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt vocalization of words
Number of subjects: 74
Study 10972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movement at slow speed (Experiment 2)
Number of subjects: 74
Study 8666450 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmandibular implant group
Number of subjects: 95
Study 8666450 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosseous implant group
Number of subjects: 95
Study 8666450 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional complete dentures)
Number of subjects: 95
Study 8666450 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction, complaints, and subjective chewing ability
Number of subjects: 95
Study 1730190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g i.v. t.i.d.
Number of subjects: 34
Study 1730190 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g every 24 hr
Number of subjects: 34
Study 1730190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and Ceftriaxone (both groups)
Number of subjects: 34
Study 4053132 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic-based antihypertensive therapy regimens
Number of subjects: 72
Study 31626127 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-Emotive Behavior Therapy (REBT) for 10 weeks with 8 weeks follow-up
Number of subjects: 154
Study 31626127 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 154
Study 28726525 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol/marijuana education
Number of subjects: 153
Study 28726525 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI)
Number of subjects: 153
Study 26804064 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise multidisciplinary intervention (STA OP!)
Number of subjects: 288
Study 26804064 — intervention group
Group type: COMPARATOR
Intervention: Control condition (general nursing skills, dementia management, and pain training)
Number of subjects: 288
Study 23934088 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate as a desensitizing agent 30 min before bleaching with 28% hydrogen peroxide activated by LED
Number of subjects: 32
Study 23934088 — intervention group
Group type: COMPARATOR
Intervention: Glycerin as a placebo
Number of subjects: 32
Study 22529265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) with gemcitabine and carboplatin (GC)
Number of subjects: 484
Study 22529265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) with gemcitabine and carboplatin (GC)
Number of subjects: 484
Study 20517330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-soluble vitamin supplementation
Number of subjects: 1078
Study 18480825 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0
Study 18480825 — intervention group
Group type: COMPARATOR
Intervention: Control (no testosterone treatment)
Number of subjects: 0
Study 16164657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (4 doses of 255 mg iron in 2 weeks or 2 doses of 510 mg iron in 1 to 2 weeks)
Number of subjects: 21
Study 12553779 — intervention group
Group type: EXPERIMENTAL
Intervention: Message appeals tailored to low idiocentrics
Number of subjects: 0
Study 12553779 — intervention group
Group type: EXPERIMENTAL
Intervention: Message appeals tailored to high idiocentrics
Number of subjects: 0
Study 12553779 — intervention group
Group type: EXPERIMENTAL
Intervention: Message appeals for low self-monitors
Number of subjects: 0
Study 12553779 — intervention group
Group type: EXPERIMENTAL
Intervention: Message appeals for high self-monitors
Number of subjects: 0
Study 11401916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of DFMO
Number of subjects: 18
Study 11401916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of DFMO
Number of subjects: 18
Study 11401916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9462972 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal treatment
Number of subjects: 73
Study 9462972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 1337459 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28
Study 1337459 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study 3896411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 8
Study 3896411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 200 mg
Number of subjects: 8
Study 3896411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 300 mg
Number of subjects: 8
Study 3896411 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen placebo
Number of subjects: 8
Study 3896411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (all doses combined)
Number of subjects: 8
Study 29772111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg
Number of subjects: 282
Study 29772111 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG) 5000 IU injections twice weekly
Number of subjects: 282
Study 29772111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Clomiphene citrate and hCG (CC + hCG)
Number of subjects: 282
Study 27578477 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg tiotropium
Number of subjects: 13
Study 27578477 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg glycopyrronium
Number of subjects: 13
Study 24573184 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2)
Number of subjects: 48
Study 24573184 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 48
Study 24573184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22817672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative warming with a forced air warming device
Number of subjects: 0
Study 22817672 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed intraoperative irrigation solutions
Number of subjects: 0
Study 22817672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preoperative warming and warmed intraoperative irrigation solutions
Number of subjects: 0
Study 22817672 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 0
Study 20405054 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day) alone for 6 weeks
Number of subjects: 172
Study 20405054 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day) + Ivermectin (150 microg/kg) at +4 months
Number of subjects: 172
Study 20405054 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline only
Number of subjects: 172
Study 20405054 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin only
Number of subjects: 172
Study 20405054 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day)
Number of subjects: 172
Study 20405054 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and Ivermectin
Number of subjects: 172
Study 18712044 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 72
Study 18712044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 72
Study 15964448 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg per day for 8 weeks)
Number of subjects: 72
Study 15964448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 12574183 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (Tgz) 600 mg/d for 3 months
Number of subjects: 10
Study 12574183 — intervention group
Group type: COMPARATOR
Intervention: Control group (OBW, N=13)
Number of subjects: 10
Study 12389267 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-reduction psychoeducation intervention
Number of subjects: 0
Study 10645516 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 63
Study 10645516 — intervention group
Group type: COMPARATOR
Intervention: Acipimox (750 mg/day)
Number of subjects: 63